Skip to main content
SpringerLink
Log in

Treatment of transplant-eligible patients

  • Chapter
  • First Online:
Handbook of Multiple Myeloma

  • 1212 Accesses

Abstract

Multiple myeloma (MM) patients up to the ages of 65–70 years without prohibitive comorbidities are eligible for autologous stem cell transplantation (auto-SCT). For these patients initial treatment can typically be divided into four phases: induction therapy, intensification with high-dose treatment (HDT) plus auto-SCT, consolidation and maintenance. These four phases will be discussed in this chapter; the role of allogeneic stem cell transplantation (allo-SCT) in MM patients will be also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 69.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Harousseau JL, Moreau P. Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med. 2009 Jun 18;360:2645-2654.

    Google Scholar 

  2. Lokhorst HM, van der Holt B, Zweegman S, et al. A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood. 2010;115:1113-1120.

    Google Scholar 

  3. Morgan GJ, Davies FE, Gregory WM, et al. Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica. 2012;97:442-450.

    Google Scholar 

  4. Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010;28:4621-4629.

    Google Scholar 

  5. Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012;30:2946-2955.

    Google Scholar 

  6. Cavo M, Tacchetti P, Patriarca F, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. Lancet. 2010;376:2075-2085.

    Google Scholar 

  7. Moreau P, Avet-Loiseau H, Facon T, et al. Bortezomib plus dexamethasone versus reduceddose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma. Blood. 2011;118:5752-5758.

    Google Scholar 

  8. Rosinol L, Oriol A, Teruel AI, et al. Maintenance therapy after stem-cell transplantation for multiple myeloma with bortezomib/thalidomide vs. thalidomide vs. alfa2b-interferon: final results of a phase III Pethema/GEM randomized trial. ASH Annual Meeting Abstracts. 2012;120:334.

    Google Scholar 

  9. Mohty M, Harousseau JL. Treatment of autologous stem-cell transplant eligible multiple myeloma patients : tenquestion and answers. Haematologica. 2014;99:408-416.

    Google Scholar 

  10. Cavo M, Rajkumar SV, Palumbo A, et al. International Myeloma Working Group consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem cell transplantation. Blood. 2011;117:6063-6073.

    Google Scholar 

  11. Moreau P, Avet-Loiseau H, Harousseau JL, Attal M. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol. 2011;29:1898-1906.

    Google Scholar 

  12. Rosinol L, Oriol A, Teruel AI, et al. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. Blood. 2012;120:1589-1596.

    Google Scholar 

  13. Kumar S, Flinn I, Richardson PG, et al. Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma. Blood. 2012;119:4375-4382.

    Google Scholar 

  14. Ludwig H, Viterbo L, Greil R, et al. Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma. J Clin Oncol. 2013;31:247-255.

    Google Scholar 

  15. Moreau P, Attal M, Pegourie B, et al. Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial. Blood. 2011;117:3041-3044.

    Google Scholar 

  16. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med. 1996;335:91-97.

    Google Scholar 

  17. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875-1883.

    Google Scholar 

  18. Koreth J, Cutler CS, Djulbegovic B, et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007;13:183-196.

    Google Scholar 

  19. Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371:895-905.

    Google Scholar 

  20. Attal M, Harousseau JL, Facon T, et al. Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med. 2003;349:2495-2502.

    Google Scholar 

  21. Barlogie B, Tricot G, Rasmussen E, et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood. 2006;107:2633-2638.

    Google Scholar 

  22. Ladetto M, Pagliano G, Ferrero S, et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol. 2010;28:2077-2084.

    Google Scholar 

  23. Cavo M, Pantani L, Petrucci MT, et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood. 2012;120:9-19.

    Google Scholar 

  24. Mellqvist UH, Gimsing P, Hjertner O, et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial. Blood. 2013;121:4647-4654.

    Google Scholar 

  25. Leleu X, Fouquet G, Hebraud B, et al. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma. Leukemia. 2013;27:2242-2244.

    Google Scholar 

  26. Stem cell transplant with lenalidomide maintentance in patients with multiple myeloma (BMT CTN 0702). https://clinicaltrials.gov/ct2/show/NCT01109004. Accessed May 22, 2015.

  27. Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012;119:7-15.

    Google Scholar 

  28. Ludwig H, Durie BG, McCarthy P, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood. 2012;119:3003-3015.

    Google Scholar 

  29. Spencer A, Prince HM, Roberts AW, et al. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol. 2009;27:1788-1793.

    Google Scholar 

  30. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1782-1791.

    Google Scholar 

  31. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366:1770-1781.

    Google Scholar 

  32. McCarthy P, Owzar K, Hofmeister C et al. Analysis of Overall Suvival (OS) in the Context of Cross-Over from Placebo to Lenalidomide and the Incidence of Second Primary Malignancies (SPM) in the Phase III Study of Lenalidomide versus Placebo Maintenance Therapy Following Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma (MM) CALGB (Alliance) ECOG BMTCTN. Clinical Lymphoma Myeloma and Leukemia. 2013;13:S28.

    Google Scholar 

  33. Maintenace therapy using lenalidomide in myeloma (IFM2005-02). https://clinicaltrials.gov/ct2/show/NCT 00430365?term=NCT 00430365&rank=1. Accessed May 22, 2015.

  34. Myeloma cure project : prospective trial of indefinite revlimid maintenance versus observation for currently event-free patients with multiple myeloma. https://clinicaltrials.gov/ct2/show/NCT 01621672?term=NCT 01621672&rank=1. Accessed May 22, 2015.

  35. Kaufman J, Nooka A, Muppidi S, et al. Survival outcomes of early autologous stem cell transplant (ASCT) followed by lenalidomide, bortezomid, and dexamethasone (RVD) maintenance in patients with high-risk multiple myeloma (MM). J Clin Oncol. 2012;30(suppl; abstr 8100).

    Google Scholar 

  36. Moreau P, Pylypenko H, Grosicki S, et al. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011;12:431-440.

    Google Scholar 

  37. Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol. 2000;18:3031-3037.

    Google Scholar 

  38. van Bergen CA, Kester MG, Jedema I, et al. Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene. Blood. 2007;109:4089-4096.

    Google Scholar 

  39. Gahtron G et al, Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma : a comparison between transplants performed 1983—93 and 1994-1998 at European Group for Blood and Marrow Transplantation centres. Br J Haematol. 2001, 113(1) : 209-16

    Google Scholar 

  40. Bjorkstrand B, Iacobelli S, Hegenbart U, et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol. 2011;29:3016-3022.

    Google Scholar 

  41. Krishnan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011;12:1195-1203.

    Google Scholar 

  42. Shimoni A, Hardan I, Ayuk F, et al. Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up. Cancer. 2010;116:3621-3630.

    Google Scholar 

  43. Patriarca F, Einsele H, Spina F, et al. Allogeneic stem cell transplantation in multiple myeloma relapsed after autograft: a multicenter retrospective study based on donor availability. Biol Blood Marrow Transplant. 2012;18:617-626.

    Google Scholar 

  44. Auner HW, Szydlo R, van Biezen A, et al. Reduced intensity -conditioned allogeneic stem cell transplantation for multiple myeloma relapsing or progressing after autologous transplantation: a study by the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2013;48:1395-1400.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Université Pierre and Marie Curie, Hospital Saint-Antoine, Paris, France

    Mohamad Mohty

  2. French National Institute for Medical Research, Nantes, France

    Florent Malard

  3. Centre René Gauducheau, Nantes Atlantique (Saint-Herblain), France

    Jean-Luc Harousseau

Authors
  1. Mohamad Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Florent Malard
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jean-Luc Harousseau
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Clinical Hematology and Cellular Therapy Department, Université Pierre and Marie Curie, Hospital Saint-Antoine, Paris, Paris, France

    Mohamad Mohty

  2. Department of Hematology, Centre René Gauducheau, Nantes Atlantique (Saint-Herblain), Nantes, France

    Jean-Luc Harousseau

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Mohty, M., Malard, F., Harousseau, JL. (2015). Treatment of transplant-eligible patients. In: Mohty, M., Harousseau, JL. (eds) Handbook of Multiple Myeloma. Adis, Cham. https://doi.org/10.1007/978-3-319-18218-6_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-18218-6_3

  • Published:

  • Publisher Name: Adis, Cham

  • Print ISBN: 978-3-319-18217-9

  • Online ISBN: 978-3-319-18218-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation